ArticleDiscover oncology2025
Mendelian randomization analysis of lipidomic profiles and thyroid cancer risk in European populations.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Thyroid cancer (TC) remains a prevalent malignancy with a rising incidence worldwide, yet the causal relationship between the plasma lipidome and TC is still poorly understood. This study aims to explore this relationship using two-sample Mendelian randomization (MR) analysis. We analyzed genetic variants associated with 179 lipid species from a genome-wide association study (GWAS) of the plasma lipidome, as well as data on TC and its subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), from the FinnGen consortium. The primary analysis was conducted using the inverse variance weighted (IVW) method, with additional validation through other MR approaches. Sensitivity analyses were also performed to assess the robustness of the results. Our MR analysis revealed significant causal associations between the plasma lipidome and the risks of TC, PTC, and FTC. For TC, sphingomyelin (d36:1) was associated with a reduced risk (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.75-0.97, p = 0.0146), while triacylglycerol (56:8) (OR = 1.18, 95% CI = 1.02-1.37, p = 0.0233), triacylglycerol (50:1) (OR = 1.24, 95% CI = 1.03-1.49, p = 0.0244) and phosphatidylethanolamine (O-18:2_20:4) (OR = 1.31, 95% CI = 1.09-1.57, p = 0.0033) were associated with an increased risk. For PTC, sterol ester (27:1/20:3) was potentially protective (OR = 0.84, 95% CI = 0.73-0.97, p = 0.0137), while phosphatidylcholine (16:0_22:6) (OR = 1.29, 95% CI = 1.05-1.59, p = 0.0175) and phosphatidylethanolamine (O-18:2_20:4) (OR = 1.45, 95% CI = 1.17-1.78, p = 0.0005) were linked to a higher risk. For FTC, phosphatidylcholine (18:2_18:2) (OR = 1.67, 95% CI = 1.04-2.70, p = 0.0351), sterol ester (27:1/18:0) (OR = 1.69, 95% CI = 1.05-2.74, p = 0.0320), triacylglycerol (54:3) (OR = 1.71, 95% CI = 1.08-2.73, p = 0.0233), phosphatidylcholine (18:0_0:0) (OR = 1.80, 95% CI = 1.01-3.21, p = 0.0450), triacylglycerol (48:3) (OR = 1.96, 95% CI = 1.13-3.40, p = 0.0159), triacylglycerol (50:4) (OR = 2.12, 95% CI = 1.30-3.45, p = 0.0024), triacylglycerol (58:8) (OR = 2.17, 95% CI = 1.24-3.80, p = 0.0065), triacylglycerol (51:3) (OR = 2.19, 95% CI = 1.31-3.64, p = 0.0027), and triacylglycerol (49:1) (OR = 2.28, 95% CI = 1.16-4.49, p = 0.0167) were linked to an increased risk, with no protective lipid identified. This study underscores the distinct effects of lipid molecular structures on TC subtypes, offering insights into potential therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.